Cardiac Arrest Treatment Market - Growth, Trends And Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||927865|
|出版日期||內容資訊||英文 120 Pages
|心臟麻痺治療市場:成長，趨勢，預測(2020∼2025) Cardiac Arrest Treatment Market - Growth, Trends And Forecast (2020 - 2025)|
|出版日期: 2020年03月01日||內容資訊: 英文 120 Pages||
The Cardiac Arrest Treatment Market studied was anticipated to grow with a CAGR of nearly 4.8% during the forecast period. The major factors driving the growth of the market are the increasing prevalence of various coronary heart diseases, cardiomyopathy which is leading to cardiac arrest deaths, favourable reimbursement initiatives and rise in geriatric population. For instance, according to Global Health And Wellness Report published in 2018, nearly 40% of the adult population in United States were diagnosed with a cardiovascular condition in the United States which directly resulted in higher demand for highly efficient, immediate treatment, and better technological advanced cardiovascular devices to save the life of the patients fueling the growth of the market throughout the forecasted period.
The Drug Segment is Expected to Hold the Largest Market Share in the Cardiac Arrest Treatment Market
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall cardiac arrest treatment market throughout the forecast period. The major factors attributing to the growth are a rise in the global prevalence of multiple cardiovascular indications like CAD, strokes and atrial fibrillation along with the rise in chronic diseases such as diabetes & obesity necessitating efficient cardiac arrest treatment. For instance, according to The American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases among which CAD was the major cause of death resulted in higher demand for better treatment technologies driving the market in the United States contributing to the outstanding share of revenue propelling the global cardiac arrest treatment market throughout the forecasted period.
The cardiac arrest market is moderately competitive and consists of several major players. Few of the key players are developing the novel product and technologies to compete with the existing products while others are acquiring and partnering with the other companies trending in the market. For instance, in January 2017, Abbott acquired St. Jude Medical, expanded its medical device segment globally by adding breakthrough inventions of SJM to its existing product portfolio of cardiovascular devices such as the Quadra Allure MP CRT-P, used as cardiac resynchronization therapy in managing cardiac failure which is further expected to foster the global cardiac arrest market growth throughout the forecast period. Some of the companies which are currently dominating the market are Koninklijke Philips N.V, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, and Novartis AG.